Physicians' Academy for Cardiovascular Education

Angiotensin receptor-neprilysin inhibitor reduces HbA1c levels

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

Presented at ACC.17 by Jelena Seferovic

Mar. 21, 2017 - news

Background

Many patients with heart failure (HF) also have diabetes. The prevalence of diabetes is around 35-40% in patients with HF. Diabetes is a major risk factor in HF and is strongly linked to progression of the disease.

Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) and indicated to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in patients with chronic HF with reduced ejection fraction (HFrEF). In the PARADIGM-HF study, it showed decreased morbidity and mortality compared to the angiotensin-converting enzyme inhibitor (ACEi) enalapril. Remarkably, the number of patients with new-onset diabetes was very small during the course of the trial.

Therefore, the effect of sacubitril/valsartan on HbA1c was investigated in this post-hoc analysis of the PARADIGM-HF trial, which included 3778 HFrEF patients with diabetes or those who had baseline HbA1c ≥6.5%. Levels were measured after 1, 2 and 3 years of follow-up and compared with these of enalapril-treated patients. Furthermore, the initiation of oral antihyperglycemic or insulin therapy during the study was evaluated.

Main results

Conclusion

Treatment of HFrEF diabetes patients with sacubitril/valsartan was associated with greater reductions in HbA1c compared with enalapril treatment. Moreover, fewer sacubitril/valsartan-treated patients needed initiation of insulin therapy. These data suggest that, in addition to providing HF benefit, sacubitril/valsartan helps to tighten glycemic control among HF patients with diabetes. This beneficial metabolic effect is most likely secondary to the inhibition of neprilysin and consequent modulation of its circulating substrates and should be further investigated.

Disclosures

Our coverage of ACC.17 is based on the information provided during the congress.

This study was simultaneously published in The Lancet Diabetes & Endocrinology